MedTrace Logo

S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma

NCT00109889 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2017-04-24

No results posted yet for this study

Summary

RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI) and fludeoxyglucose F 18 positron emission tomography (\^18FDG-PET) may help diagnose solitary plasmacytoma.

PURPOSE: This clinical trial is studying MRI and \^18FDG-PET to see how well they work in diagnosing patients with solitary plasmacytoma.

Conditions

Interventions

PROCEDURE

magnetic resonance imaging

magnetic resonance imaging (MRI)

PROCEDURE

positron emission tomography

positron emission tomography (PET)

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Andrzej J. Jakubowiak, MD, PhD · University of Michigan Rogel Cancer Center

  • Janet S. Biermann, MD · University of Michigan Rogel Cancer Center

  • Paul Okunieff, MD · James P. Wilmot Cancer Center

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2007-04-30
Completion
2007-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00109889 on ClinicalTrials.gov